Synaptogenix Announces FDA Authorization Of Its Investigational New Drug Application For Bryostatin-1 Trial In Multiple Sclerosis
Portfolio Pulse from Benzinga Newsdesk
Synaptogenix has received FDA authorization for its Investigational New Drug (IND) application to conduct a trial of Bryostatin-1 in treating Multiple Sclerosis.
June 26, 2024 | 1:13 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Synaptogenix has received FDA authorization for its IND application to conduct a trial of Bryostatin-1 in treating Multiple Sclerosis. This regulatory milestone is a positive development for the company.
FDA authorization for an IND application is a significant regulatory milestone that can positively impact the company's stock price. It indicates progress in the development of Bryostatin-1, which could lead to future revenue if the trial is successful.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100